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Abstract
Background
Participants in clinical trials frequently fail to appreciate key differences between research
and clinical care. This phenomenon, known as therapeutic misconception, undermines
informed consent to clinical research, but to date there have been no effective interventions
to reduce it and concerns have been expressed that to do so might impede recruitment. We
determined whether a scientific reframing intervention reduces therapeutic misconception
without significantly reducing willingness to participate in hypothetical clinical trials.
Methods
This prospective randomized trial was conducted from 2015 to 2016 to test the efficacy of
an informed consent intervention based on scientific reframing compared to a traditional
informed consent procedure (control) in reducing therapeutic misconception among patients
considering enrollment in hypothetical clinical trials modeled on real-world studies for one of
five disease categories. Patients with diabetes mellitus, hypertension, coronary artery dis-
ease, head/neck cancer, breast cancer, and major depression were recruited from medical
clinics and a clinical research volunteer database. The primary outcomes were therapeutic
misconception, as measured by a validated, ten-item Therapeutic Misconception Scale
(range = 10–50), and willingness to participate in the clinical trial.
Results
154 participants completed the study (age range, 23–87 years; 92.3% white, 56.5% female);
74 (48.1%) had been randomized to receive the experimental intervention. Therapeutic mis-
conception was significantly lower (p = 0.004) in the scientific reframing group (26.4, 95% CI
[23.7 to 29.1] compared to the control group (30.9, 95% CI [28.4 to 33.5], and remained so
after controlling for education (p = 0.017). Willingness to participate in the hypothetical trial
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was not significantly different (p = 0.603) between intervention (52.1%, 95% CI [40.2% to
62.4%]) and control (56.3%, 95% CI [45.3% to 66.6%] groups.
Conclusions
An enhanced educational intervention augmenting traditional informed consent led to a
meaningful reduction in therapeutic misconception without a statistically significant change
in willingness to enroll in hypothetical clinical trials. Additional study of this intervention is
required in real-world clinical trials.
Introduction
Clinical trials ask one or more basic scientific questions: Is a particular intervention safer,
more tolerable, or more effective than other approaches to a given health condition? To
answer this question, a protocol often involves randomization to one or more intervention
arms, blinding of researchers and participants, constraints on dosing, limiting adjunctive
treatments, and additional testing (e.g., biopsies, blood draws, imaging) to determine the
consequences of an intervention. Such procedures depart dramatically from ordinary medi-
cal practice. Indeed, their use in routine medical care might be unethical because they limit
the tailoring of treatment to patients’ individual needs and risk exposing patients to unneces-
sary harms.
Yet participants across a wide range of clinical research settings and trial designs often do
not appreciate adequately how these indispensable features of trial research differ from the
care they would otherwise receive outside of a study [1–4]. When clinical research participants
fail to grasp key differences between participating in a clinical trial and receiving ordinary clin-
ical care, they are said to manifest a therapeutic misconception. Previous research has sug-
gested that therapeutic misconception can manifest in three ways: 1) an incorrect belief that
treatment will be individualized to address a participant’s own needs, 2) the failure to realize
that advancing scientific knowledge (as opposed to benefitting individual participants) is the
primary purpose of a clinical trial [5], or 3) an unrealistic expectation of personal benefit from
participation based on a misunderstanding of research methods [6].
Regardless of which components of therapeutic misconception have been examined, most
studies have found that it is a common problem [2,5,6], and one that poses a challenge to the
validity of informed consent [7,8]. When participants do not understand a trial’s purpose or
how aspects of its methodology differ from usual medical care, their decision to join a research
study necessarily rests on inadequate information. Ignoring these misconceptions devalues
participants’ autonomy and dignity [8]. To date, no studies have examined ways to reduce
therapeutic misconception among research participants. This may partly reflect a concern that
participants would be unwilling to join studies if therapeutic misconceptions are dispelled
[9,10].
As described elsewhere [11], therapeutic misconception arises in part from individuals’ ten-
dency to view trial participation in a personal clinical frame, that is, with regard to their indi-
vidual illnesses and treatment needs. The current study tests whether augmentation of
traditional informed consent with an educational intervention designed to help participants
reframe the elements of a clinical trial as a test of a scientific hypothesis is effective in reducing
therapeutic misconception without decreasing willingness to participate in a clinical trial.
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Methods
Study design and participants
The University of Massachusetts Medical School (UMMS) Institutional Review Board (IRB)
approved a waiver of written informed consent for this minimal risk study; participants provided
verbal consent after viewing a fact sheet that specified that the study involved: consideration of a
hypothetical trial, viewing one of two informed consent presentations, and completion of a survey.
Participants were compensated $20 and provided parking vouchers as needed.
A randomized trial was conducted to evaluate an enhanced disclosure based on scientific
reframing of the methods of clinical trials for participants from five broad disease groups (car-
diac disorders, cancer, diabetes, hypertension, and depression). Eligible individuals were all
English-speaking adults (over 18) currently receiving treatment for the one of the five disease
groups, who were not currently in and who clinicians did not expect would be asked to partici-
pate in an actual clinical trial, not diagnosed with a psychotic disorder, and able to provide
informed consent. Individuals were excluded if they did not live within convenient traveling
distance to participate, or if the research group was unable to obtain their contact information.
Recruitment occurred from May 2015 through October 2016, in the cardiology, oncology,
psychiatry, and family medicine clinics at UMass Memorial Health Care (UMMHC) in the
United States, with procedures varying somewhat across clinics. All clinics except cardiology
had flyers placed in clinic waiting areas. In addition, clinicians in each clinic were asked to
refer eligible patients to the study. Because of the number of on-going clinical trials, cardiology
patients were pre-screened by clinical staff for eligibility before recruitment. Similarly, depres-
sion patients were pre-screened by clinicians for clinical appropriateness. Clinically referred
patients who met eligibility checks and did not contact us directly received an introductory let-
ter and a subsequent telephone call. To augment recruitment, hypertension and diabetes
patients were directly approached in clinic waiting areas. Lastly, some participants were
recruited from a UMMS research volunteer list.
Study staff screened potential participants to see if they were eligible for the study, i.e.,
receiving treatment for one of the five conditions and within convenient distance from the
medical center—by reviewing their medical records. Research staff also confirmed diagnoses,
treatment, and current non-participation in clinical trials with potential participants.
Participants were invited to learn about a hypothetical trial specific to their disease group.
They were randomized (1:1) by a computerized random number generator to one of two arms
(stratified by disease group): a control arm that was intended to mimic a standard consent pro-
cedure, and an experimental arm that provided a scientific reframing disclosure (described
below) followed by the standard consent procedure. Participants were not made aware of the
randomization process or that half of the participants would be receiving the reframing inter-
vention. Hence, they had no way of identifying the disclosure they received as either experi-
mental or control.
Procedures
All participants viewed an informed consent disclosure for a hypothetical clinical trial target-
ing the disorder for which they were receiving treatment. Disclosures were developed in con-
sultation with researcher-clinicians who had expertise in conducting trials for one of the five
disease groups. The trials and corresponding informed consent disclosures were designed to
reflect current, real-world, randomized controlled trials as listed on clinicaltrials.gov or as
identified by the researcher-clinicians: 1) for cardiovascular disease, a trial comparing an
experimental anti-inflammatory medication targeting atherosclerosis versus statin therapy
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(control) following intracoronary stent placement; 2) for cancer, either a) a trial comparing
two experimental medications, each given in addition to a standard medication for locally
recurrent or metastatic breast cancer, or b) a trial comparing radiation, cisplatin, and an exper-
imental drug against radiation, cisplatin and a standard medication for head/neck cancer; 3)
for major depression, a trial comparing an experimental intravenous medication versus a keta-
mine-like infusion for treatment-resistant major depression; 4) for diabetes mellitus, a trial
comparing an experimental, ultra-rapid-acting inhaled insulin versus an approved inhaled
insulin, 5) for hypertension, a trial comparing an approved versus an experimental direct
renin inhibitor. All disclosures were embodied in a slide set with professional narration, which
participants viewed on a tablet computer.
Prior to viewing the informed consent disclosure, the experimental group also viewed a sci-
entific reframing intervention. Scientific reframing focused on providing education regarding
the rationale behind clinical trials and the specific differences between clinical trial research and
clinical care. This included five content areas: 1) That the purpose of the research is to assess
whether the experimental intervention is more or less effective than the standard (control) treat-
ment; that the reason the researchers are interested in doing this study is that they genuinely do
not know whether the experimental treatment is better than the current standard of care; and
that if they knew it was better there would be no need to do the study; 2) A description of ran-
domization, including both the logic behind randomization (i.e., minimizing the risk of selec-
tion bias in assignment to the different arms of the study) and the inability of the researcher to
affect assignment; 3) Limitations on dosage and adjunctive medications and why such limita-
tions are important to the validity of the study; 4) The blinding of the subject and the physician
as to which medication the subject is getting and how that will protect the study design from
expectation bias; 5) That all of the above are done only to improve the scientific design and thus
assure that the results of the study are valid and not to improve the care of the people in the
study. In order to promote comprehension, particularly among individuals with lower literacy
and/or visual impairments, the scientific reframing intervention was administered in a comput-
erized slideshow, with professionally narrated slides containing text and animations to retain
subjects’ interest and attention. The slides auto-advanced and took 12 minutes to view.
Both the informed consent disclosures and the scientific reframing intervention used in
this study are publicly accessible at https://www.youtube.com/UMassSPARC/.
Outcomes
Upon completion of the informed consent and (for the experimental group) reframing proce-
dures, participants were provided a link to a RedCap survey. Each section of the survey had to
be completed before moving to the next; once submitted, answers could not be reviewed or
changed. All participants were given the option of having the survey items read to them in an
interview format. The survey items were primarily self-administered, except for nine individu-
als who requested that items and response options be read aloud to them. Five of these partici-
pants reported a visual, hearing, or reading impairment. To assess willingness to participate in
the hypothetical trial, participants were asked: “If you had to decide right now, would you
decide to participate or not?” Therapeutic misconception was assessed using a ten-item mea-
sure previously developed and validated among 220 clinical trial participants (range 10–50)
[12]. Participant demographic and background information were also collected.
Statistical analysis
SPSS statistical software (version 23) was used for all analyses. To detect a minimal difference
of 5 units in the therapeutic misconception score (which, based on the distribution of scores
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from the validation study of the measure [12], corresponds to a meaningful difference in thera-
peutic misconception), with type I error of 5% (2-sided) and 80% power, a target sample size
was set at 154 participants, large enough to detect an effect size of 0.4025. Two-tailed t tests
were used to compare unadjusted mean therapeutic misconception scores by intervention
group, and a chi-square test was used to compare the percentage of participants willing to par-
ticipate in the hypothetical trial. Factorial two-way ANOVAs were used to determine main
and interaction effects of group assignment and select baseline characteristics on therapeutic
misconception.
Results
Between May 1, 2015 through October 31, 2016, two hundred thirty-two eligible patients were
identified through all referral mechanisms combined (Fig 1). Of these, a total of 158 individu-
als (68%) consented to participate in the study: 82 were randomized into the control condition
and 76 into the scientific reframing condition. After randomization, 1 participant in the con-
trol group quit the study. Two participants in the reframing group and 1 in the control group
were omitted from the analysis due to a subsequent determination of ineligibility (i.e., a partic-
ipant lacked fluency in English, another presented with cognitive disabilities, and a third later
revealed that they were no longer receiving treatment for one of the index disorders). In all, 80
individuals in the control arm and 74 in the scientific reframing arm completed the study.
Participants’ mean age was approximately 55.9 years (Table 1). A majority were non-Latino
(94.8%), white (90.3%), and female (56.5%); 37.0% had completed a college degree or higher;
and 72.4% reported that they had not been employed in healthcare, higher education, or
research.
Therapeutic misconception
Therapeutic misconception scores were significantly lower in the scientific reframing group
(24.9, 95% CI [21.8 to 28.0]) compared to the control group (30.9, 95% CI [28.3 to 33.5]), with
a mean difference of 6 points, 95% CI [1.97 to 10.04], (p = 0.004) (Table 2).
There was no significant main effect of disease group on therapeutic misconception scores,
F(4,144) = 0.70, p = 0.594, and no significant interaction between disease group and interven-
tion, F(4,144) = 0.45, p = 0.771.
Given previous data suggesting an inverse relationship between level of education and ther-
apeutic misconception, we examined the effect of intervention and educational level concur-
rently and found that there was a significant main effect of educational level, F(2,148) = 17.2,
p<0.001 (i.e., people with more education manifested lower levels of therapeutic misconcep-
tion); the 95% CI around the b interaction coefficient of -7.15 was [-13.19 to -1.11]. The inter-
action between educational level and intervention was non-significant, F(2,148) = 0.54,
p = 0.586; the 95% CI around the b coefficient of 3.39 was [-5.26 to 12.05]. See Fig 2.
Willingness to participate
Expressed willingness to participate in the hypothetical clinical trial between scientific refram-
ing (n = 38, 52.4%, 95% CI [40.2 to 62.4]) and control groups (n = 45, 56.3%, 95% CI [45.3 to
66.6]) did not differ to a significant degree (p = 0.603); see Table 2. Irrespective of intervention
group, therapeutic misconception did not differ significantly (p = 0.91) between those who
expressed willingness to participate (27.9, 95% CI [25.1 to 30.9]) and those who did not (27.8,
95% CI [24.6 to 30.8]).
Reducing therapeutic misconception
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Discussion
Therapeutic misconception is an important and prevalent ethical problem in consent to clinical
trials [1,7]. Poor appreciation of the core differences between clinical research and clinical care
jeopardizes the validity of informed consent to trial participation. In this randomized trial, sci-
entific reframing through an educational intervention was associated with a significant reduc-
tion in therapeutic misconception. The decrease in therapeutic misconception scores, a mean
difference of six points, corresponds to a change from incorrect to correct answers on two or
three items of this ten-item scale, or a reduction in strength of incorrect responses across a
larger number of items. Consistent with past research [1–3], therapeutic misconception was
higher among those with less educational attainment, although participants in the intervention
group showed evidence of reduced therapeutic misconception across all education levels. To
Fig 1. Flow diagram of a randomized trial comparing scientific reframing plus informed consent vs informed
consent alone on therapeutic misconception in adults considering hypothetical clinical trial enrollment in 1
of 5 medical domains.
https://doi.org/10.1371/journal.pone.0184224.g001
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our knowledge, this is the first study to demonstrate the efficacy of an intervention specifically
designed to reduce therapeutic misconception among patients similar to those who would be
recruited for clinical trials. An appropriate next step is to test this intervention on participants
in real clinical trials; based on the findings from this study, we would hypothesize that partici-
pants in actual trials will respond similarly to those in this study.
Despite previous concerns that efforts to dispel therapeutic misconception might deter
individuals from enrolling in clinical trials, this study found preliminary evidence that willing-
ness to participate did not differ between those in the intervention and control groups to a sta-
tistically significant degree. This finding and the observed interaction between education and
the study intervention merit further examination as the present study was not powered to
detect predetermined differences on these variables.
These findings have important implications for the current approach to conducting
informed consent for clinical trials. Consent discussions customarily focus on the specific
Table 1. Participant characteristics, overall and by intervention group.
Characteristic Total No. of Participants (n = 154) Control (n = 80) Scientific Reframing (n = 74)
N(%)
Gender (male) 67(43.5) 36(45.0) 31(41.9)
Hispanic/Latino Ethnicity 8(5.2) 3(3.8) 5(6.8)
Race
White 139(90.3) 71(88.8) 68(91.9)
Black 7(4.5) 5(6.3) 2(2.7)
Asian 2(1.3) 1(1.3) 1(1.4)
More than one race 6(3.9) 3(3.8) 3(4.1)
Educational Level
High school degree or less 43(27.9) 25(31.3) 18(24.3)
Some college or trade school 54(35.1) 30(37.5) 24(32.4)
College degree or more 57(37.0) 25(31.3) 32(43.2)
Employmenta
Health care, higher education, and research 42(27.6) 24(30.0) 19(26.0)
Other 110(72.4) 56(70.0) 54(74.0)
Disease Group
Cardiology 30(19.5) 16(20.0) 14(18.9)
Oncology 30(19.5) 14(17.5) 16(21.6)
Depression 35(22.7) 19(23.8) 16(21.6)
Diabetes 33(21.4) 17(21.3) 16(21.6)
Hypertension 26(16.9) 14(17.5) 12(16.2)
Age, yearsb M(SD)
55.9(12.1) 55.4(11.2) 56.5(13.1)
a Employment for one participant in the scientific reframing group was not reported.
b For participants for whom exact age was unknown (n = 9), the median value from the specified age range was used.
https://doi.org/10.1371/journal.pone.0184224.t001
Table 2. Therapeutic misconception and willingness to participate, by intervention group.
Control (n = 80) Scientific Reframing (n = 74) p value
Mean score [95% CI]
Therapeutic Misconception 30.9 [28.3 to 33.5] 24.9 [21.8 to 28.0] 0.004
% [95% CI]
Willingness to Participate 56.3 [45.3 to 66.6] 52.4 [40.2 to 62.4] 0.603
https://doi.org/10.1371/journal.pone.0184224.t002
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features of a trial, including the study’s purpose and procedures, and the potential risks and
benefits of participation. Although this approach appropriately highlights the unique charac-
teristics of the experimental intervention being tested, research suggests that when potential
participants hear this information they tend to incorporate it into their existing cognitive
framework based on their own illnesses and personal needs [11]. In other words, many view
participation in a clinical trial as an extension of their treatment without necessarily grasping
the broader, fundamental differences between clinical research and ordinary clinical care. The
educational intervention tested in this study was designed to shift participants’ framework to
help them appreciate how such differences undergird the validity of the scientific data that
clinical trials seek to provide and, therefore, how clinical trials differ from accepted medical
treatment. Much of the content included in the intervention has been characterized as essential
for optimizing informed consent under a shared decision-making framework [13–15].
The design of the reframing intervention has additional strengths. First, the information
that is covered, which clearly goes beyond what is disclosed in a typical informed consent
discussion, is relevant to a variety of clinical trial designs and thus can be applied with little or
no modification to many other trial settings. Moreover, by administering the intervention
prior to the typical informed consent discussion, prospective participants are given a context
in which to incorporate subsequent information about the trial to which they are being
recruited. In this regard, the intervention may be preventing, as opposed to merely correcting,
Fig 2. Group differences in therapeutic misconception scores by educational level.
https://doi.org/10.1371/journal.pone.0184224.g002
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therapeutic misconception. Third, in its current form, the intervention is 12 minutes long,
which amounts to a fraction of the time required for an informed consent discussion in a typi-
cal clinical trial.
Clinical trials often experience difficulty meeting target recruitment goals [16], and some
authors have speculated that redressing therapeutic misconception might further slow clinical
trial recruitment [9,10]. In the present study, those who received the intervention were not less
interested to a statistically significant degree in participating than those in the control group,
nor did therapeutic misconception scores differ between those inclined to participate and
those who were not. Although we know of no other work examining the impact of an interven-
tion to address therapeutic misconception on enrollment decisions, a recent review of other
audio-visual informed consent interventions found they do not undermine clinical trial
recruitment and that their effect on understanding is extremely low [17]. As noted, however,
our finding requires replication with attention paid to whether reducing therapeutic miscon-
ception affects both recruitment and retention in large clinical trials. Nevertheless, if this find-
ing is confirmed, it should not be surprising. People have a variety of reasons for enrolling in
clinical trials, including altruism, and many individuals without therapeutic misconception
may have realistic estimates of receiving some degree of personal benefit. Put another way,
redressing therapeutic misconception does not require pessimism on the part of potential par-
ticipants about what a clinical trial may provide. Indeed, clinical trials can grant patients access
to resources that may be otherwise unavailable, including promising investigational agents,
expert medical evaluation, and close monitoring of their disorders. Thus, at present, the fear
that confronting therapeutic misconception will thwart the advance of medical science seems
misplaced.
A number of study limitations should be noted. First, in response to the concern that reduc-
ing therapeutic misconception might jeopardize enrollment, we intentionally chose to test the
intervention initially in hypothetical clinical trials; this approach limits the generalizability of
study findings. An appropriate next step is to test the intervention in actual clinical trials. Sec-
ond, despite constructing hypothetical trials that reflect current clinical trial research in five
different disease categories, there are clearly a multitude of diseases that we did not include in
this study as well as other clinical trial designs, including pragmatic and placebo-controlled tri-
als. These warrant testing in the future. Third, this study was powered to detect a difference in
therapeutic misconception score but not willingness to participate, or interactions between the
outcomes and non-intervention variables. Finally, the participants in this study were dispro-
portionately white, female and well-educated; the efficacy of scientific reframing in other pop-
ulations remains to be determined.
Conclusions
In the context of hypothetical clinical trials in five medical domains, this study found that ther-
apeutic misconception can be substantially reduced through a non-burdensome scientific
reframing intervention that augments existing informed consent practices, without jeopardiz-
ing enrollment to a statistically significant degree. Given the ethical importance of therapeutic
misconception, further testing of this intervention in real-world clinical trials is warranted.
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